FOR IMMEDIATE RELEASE
- Expansion adds two ISO 7-classified clean rooms to existing laboratory infrastructure
- Investment is intended to support increased manufacturing, quality systems, and product-development capacity
- Infrastructure expansion supports Cellgenic’s growing international product portfolio
MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced an expansion of its flagship laboratory facilities in Cancun, Mexico, adding two ISO 7-classified clean rooms to the Company’s existing laboratory infrastructure.
The additional capacity is intended to support increased manufacturing capabilities, product development throughput, and quality-systems capacity as Cellgenic’s international product portfolio continues to grow — including the Company’s recently announced NK cell and MUSE cell product lines and expanded peptide delivery portfolio.
The Company characterized the investment as an important component of its long-term international growth strategy, supporting both current production volume and future product-line development.
“Manufacturing and quality infrastructure is what lets a product roadmap turn into reliable, scalable supply,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “This clean room expansion in Cancun gives Cellgenic the capacity it needs to support the product lines we’ve been bringing to market this year.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About Cellgenic
Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com
